Heshi Eye Hospital Deepens Strategic Collaboration with Johnson & Johnson Vision, Launches Asia-Pacific Center of Excellence for Presbyopia Surgery

Source: China Securities News·China Securities Network

China Securities News China Securities Network News (Reporter Song Weidong) China Securities News reporter learned on November 10 fromHe EyeIt was reported that Liaoning He Eye Hospital Group Co., LTD. recently signed a comprehensive strategic cooperation agreement with Johnson & Johnson Vision for 2026. The two parties will deepen cooperation in areas such as the enhancement of cataract diagnosis and treatment technologies, dry eye diagnosis and treatment services, and talent echelon construction. This move is not only an important measure for He Eye to implement the "Smart City of Light" strategy but also a crucial step for the company to achieve high-quality development by leveraging global premium resources. It realizes resource complementation and technical synergy, providing an innovative model for the innovation and service upgrade of the ophthalmology industry.

As a smart eye health ecosystem industry group and a technology-based listed institution, He Eye (Liaoning He Eye Hospital Group Co., LTD.) possesses abundant clinical resources and a robust fundamental research platform. With the goal of building a "Smart City of Light," the company fully leverages its advantages in the comprehensive layout of the "medical education, research, and industry" eye health industrial chain. Driven by data and cutting-edge technologies, He Eye has successively collaborated with numerous innovative technology enterprises and research institutions in areas such as genetics, stem cells, artificial intelligence, and biomedicine. These collaborations aim to introduce and absorb innovative products, ophthalmic technologies, and healthcare management concepts that are in sync with international standards. Based on a digital platform, He Eye has constructed an ecosystem for eye health management and consumer consultation services that covers the entire life cycle.

Over the years, He Eye has achieved remarkable results in high-quality ophthalmic medical services, innovative technology clinical transformation, and talent cultivation by leveraging platforms and resource advantages such as the International Council of Ophthalmology (ICO) international ophthalmologist training institution, the National Health Commission's blindness prevention and treatment training base, and the national drug clinical trial institution, laying a solid foundation for the deepening of this strategic cooperation between the two parties.

According to the agreement, He Eye and Johnson & Johnson Vision will jointly promote the clinical implementation and application of new ophthalmic technologies and products. The two parties will accelerate the application and promotion of related innovative products and technologies in the Chinese market, including the IntelliSIM Preloaded TECNIS Synergy IOL, Catalys 7.0 Femtosecond Laser System, Veritas Phacoemulsification System, Elita Femtosecond Laser Refractive Surgery Equipment, and many other ophthalmic innovations. The outcomes of this cooperation will be fully utilized in the jointly established Asia-Pacific Center of Excellence for Presbyopia Diagnosis and Treatment by both parties, establishing a comprehensive multidisciplinary diagnosis and treatment system for presbyopia, further enhancing the level of integrated treatment solutions and patients' visual quality.

"This collaboration will fully integrate Johnson & Johnson Vision’s global perspective, innovative strength, and talent development experience to promote the widespread application of cutting-edge ophthalmic technologies, high-end equipment, and personalized services in China," said Wang Xianjun, Assistant to the President of He Eye. Leveraging the advanced technology of Navigation FLACS and the Asia-Pacific Excellence Center for Presbyopia Diagnosis and Treatment Surgery by Johnson & Johnson Vision, He Eye and Johnson & Johnson Vision will achieve deep integration and value co-creation, bringing the blessing of sight to more patients.